Announced Fri, 7 Aug · 16:06 IST
Protean Q1FY27: Revenue up 19%, EBITDA margin dips to 10% on upfront costs
Mgmt Guided Margin ImprovementPromoter Disclosed Acquisition PlansOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
PROTEAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.7%1-day move
₹566.95
prior close
₹565.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5-0.4-0.5-0.4-0.7-1.5-2.0-2.6-3.3-3.7————
Up moveDown movePending
AI summary
Q1FY27 revenue grew 19% YoY to INR 251 cr but EBITDA fell 38% to INR 28 cr (margin 10%) due to INR 18 cr upfront RFP project costs. Normalized margin was 17.2%. PAT at INR 6 cr. Zero debt with INR 800+ cr cash. New MD Ajay Rajan outlined shift to solution-led approach, DPI-in-a-box model, BFSI focus, international expansion and inorganic opportunities. CFO sees substantially improved margin trajectory in 2-3 years.
Likely market impact
Near-term margins under pressure but management guides for recovery as upfront costs roll off and new strategy gains traction.